000			03995nam a22003855i 4500
001			81497
003			ES-MaUEC
005			20230207040332.0
007			cr nn 008mamaa
008			151020s2015 gw | s |||| 0|eng d
020			_a9783319219271
024	7		_a10.1007/978-3-319-21927-1 _2doi
050		4	_aRC660 _b.I545 2015
245	1	0	_aInflammatory Pathways in Diabetes : _bBiomarkers and Clinical Correlates _cedited by Michael Pugia.
250			_a1st ed. 2015.
260			_aCham, Switzerland _bSpringer _c2015
300			_a1 recurso en línea (XVI, 219 páginas) _b33 ilustraciones, 18 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aProgress in Inflammation Research
505	0		_aPart 1. Introduction -- 1. Impact of inflammation and the innate immunity response in obesity mediated diabetes (lit review) -- Part 2. Impact of complement on diabetic disease -- 2. Complement and Complement Regulatory Proteins in Diabetes -- Part 3. Role of C terminal fragment of adiponectin receptor in inhibition of insulin degradation -- 3. Development of adiponectin receptor C terminal fragment bioassays -- 4. Protease inhibition and biological distribution of the C terminal fragment of adiponectin receptor -- 5. Cell & biological models for the C terminal fragment of adiponectin receptor -- 6. C-Terminal fragment of adiponectin receptor clinical correlations -- Part 4. Uristatin assay for prediction of renal and other clinical events -- 7. Uristatin immunoassay usage in glomerular nephritis assessment -- 8. Acute Response of Uristatin in Surgery -- 9. Cardiovascular and metabolic syndrome impact on uristatin -- 10. Uristatin anti-inflammatory cellular signaling -- Part 5. Summary -- 11. Overview of progress in new markers for diabetes inflammation (Literatue Review).
520	3		_aThis book discusses recent advances in new anti- and pro-inflammatory pathways in diabetic disease, and identifies new diagnostic immunological methods that offer potential companion diagnostics for diabetic diseases. New methods in proteomics, mass spectroscopy, immunological assay design, measurement of cellular signal transduction and protease inhibition are used to clarify new biochemical pathways. Biomarker validation in animal models and correlations in humans for diagnostic clinical trials shed new light on the impact of diabetic diseases. The book reviews current understanding of inflammatory pathways in the pathophysiology of insulin resistance, metabolic syndrome, nephritis and other diabetic inflammatory conditions, and is the first to describe the impact of novel adipokines, protease inhibitors and complement markers. By presenting new methodologies for biomarker discovery, it provides a valuable resource for researchers studying clinical diagnosis, drug development, bio-analytical chemistry, proteomics and biochemistry. It is also useful for those conducting clinical and biological studies for targeted drug development. The methodologies and approaches can be applied to other markers, and the information will be helpful in the preparation of research grant applications.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGER, asignarmaterias_11febrero
650		7	_aDiabetes. _9138582 _2embne
650		7	_aInmunología _2embne _9138330
650		7	_aFarmacología _2embne _9137893
700	1		_aPugia, Michael _eeditor literario _993957 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-21927-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12900874 _b10-10-17 _c18-01-16
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aRC660 .I545 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11570490 _z06-04-17
999			_c81497 _d81497 _x1